Document:

Amendment dated as of October 31, 2007 between Biovest and Laurus Master Fund

 Exhibit 10.8 
 AMENDMENT 
 THIS AMENDMENT (this “Amendment”) is entered into as of
October 31, 2007, for effectiveness as of April 1, 2007 by and among Biovest International, Inc., a Delaware corporation (the “Company”), each of the other undersigned parties hereto other than the Holders (as defined
below) (collectively, the “Subsidiaries and Affiliate” and together with the Company, the “Credit Parties” and each, a “Credit Party”), Laurus Master Fund, Ltd., a Cayman Islands company
(“Laurus”), Valens Offshore SPV I, Ltd., a Cayman Islands company (“VOFSPVI”) and Valens Onshore SPV I, LLC., a Delaware limited liability company (“VUSSPVI” and, together with Laurus and VOFSPVI,
the “Holders” and each a “Holder”). 
 BACKGROUND 
 WHEREAS, the Company has sold to Laurus a Secured Promissory Note in the aggregate principal amount of Seven Million Seven Hundred Ninety-Nine Thousand
and 00/100 Dollars ($7,799,000.00) (as amended, modified or supplemented from time to time, the “March 2006 Note”) pursuant to the terms of the Note and Warrant Purchase Agreement, dated as of March 31, 2006 by and between the
Company and Laurus (as amended, modified or supplemented from time to time, the “Purchase Agreement”) and the Related Agreements referred to therein; 
 WHEREAS, reference is made to the (a) the Subsidiary Guaranty dated as of March 31, 2006 made by Biovax, AutovaxID, Inc, a Florida corporation (“AutovaxID”), BioLender, LLC, a Delaware
limited liability company (“Biolender”) and BioLenderII, LLC, a Delaware limited liability company (“BiolenderII”) in favor of Laurus Master Fund, Ltd., a Cayman Islands company (“Laurus”) (as
amended, modified or supplemented from time to time, the “Subsidiary Guaranty”), (b) Master Security Agreement dated as of March 31, 2006 made by the Company, Biovax, AutovaxID, Biolender and BiolenderII in favor of Laurus
(as amended, modified or supplemented from time to time, the “Master Security Agreement”), (c) Stock Pledge Agreement dated as of March 31, 2006 and made by the Company, Biovax, AutovaxID, Biolender and BiolenderII in
favor of Laurus (as amended, modified or supplemented from time to time, the “Stock Pledge Agreement”), (d) the Guaranty dated as of March 31, 2006 made by Accentia Biopharmaceuticals, Inc., a Florida corporation
(“Accentia”) in favor of Laurus (as amended, modified or supplemented from time to time, the “Accentia Guaranty”), (e) the Stock Pledge Agreement dated as March 31, 2006 and made by Accentia in favor of
Laurus (as amended, modified or supplemented from time to time, the “Accentia Stock Pledge Agreement”) and (f) the Intellectual Property Security Agreement dated as of March 31, 2006 and made by the Company in favor of
Laurus (as amended, modified or supplemented from time to time, the “IP Security Agreement”) (the Subsidiary Guaranty, the Master Security Agreement, the Stock Pledge Agreement, the Accentia Guaranty, the Accentia Stock Pledge
Agreement, the IP Security Agreement, collectively, the “Existing Security and Guaranty Agreements”). 

 WHEREAS, Laurus has since March 31, 2006 subsequently assigned its rights to portions of the March
2006 Note to each of VOFSPVI and VUSSPVI; 
 WHEREAS, the Company and each relevant Holder has agreed to make certain changes to the March
2006 Note as set forth herein. 
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Amendment to March 2006 Note. 

(a) Each Holder and the Company hereby agree that the Company shall not be required to pay the interest portion of any Monthly Amount
(as defined in the March 2006 Note) due on the first business day of each of the following months: April 2007, May 2007, June 2007, July 2007, August 2007, September 2007, October 2007, November 2007 and December
2007 on such dates (collectively the “Postponed Interest”); provided that, the Postponed Interest shall be paid in full on the earlier to occur of (i) the Maturity Date (as defined in the March 2006 Note) and (ii) the date
of a financing transaction secured by, or the sale of any assets relating to the Company’s or any of its Subsidiaries’ operations in Minnesota, other than in the ordinary course, together, in each case, with all other amounts due and
payable on such date under the Purchase Agreement and the Related Agreements referred to in the Purchase Agreement. 
 (b)
Each Holder and the Company hereby agree that the Company shall not be required to pay the principal portion of any Monthly Amount (as defined in the March 2006 Note) due on the first business day of each of the following months: August
2007, September 2007, October 2007, November 2007 and December 2007 on such dates (collectively the “Postponed Principal”); provided that, the Postponed Principal shall be paid in full on the earlier to occur of
(i) the Maturity Date (as defined in the March 2006 Note) and (ii) the date of a financing transaction secured by, or the sale of any assets relating to the Company’s or any of its Subsidiaries’ operations in Minnesota, other
than in the ordinary course, together, in each case, with all other amounts due and payable on such date under the Purchase Agreement and the Related Agreements referred to in the Purchase Agreement. 
 (c) Monthly Amount (as defined in the March 2006 Note) payments shall resume without giving effect to this Section 1 pursuant to the
terms of the March 2006 Note on January 2, 2008. 
 (d) In consideration of each Holder’s agreement to amend the
March 2006 Note and defer the payment of certain interest and principal amounts due and owing under the March 2006 Note in accordance with the terms hereof, the Company hereby agrees to pay to each Holder, or its assigns, on the Maturity Date (as
defined in the March 2006 Note) the following amounts: (i) to Laurus, $1,754,226.12 (the “Laurus Payment”), (ii) to VOFSPVI, $47,034.42 (the “Valens Offshore Payment”) and (iii) to VUSSPVI, $14,550.29
(the “Valens Onshore Payment”). 
  

 2 

 (e) With respect to the Laurus Payment, Laurus and the Credit Parties hereto agree that
the fair market value of the Laurus Payment (as reasonably determined by Laurus and the Credit Parties) received in consideration of the amendments to the March 2006 Note made by Laurus hereunder is hereby designated as interest and, accordingly,
shall be treated as a reduction of the remaining stated principal amount (which reduced principal amount shall be treated as the issue price) of the March 2006 Note for U.S. federal income tax purposes under and pursuant to Treasury Regulation
Sections 1.1001-3(e)(2)(iii), 1.1273-2(g)(2)(ii) and 1.1274-2(b)(1). The parties further agree to file all applicable tax returns in accordance with such characterization and shall not take a position on any tax return or in any judicial or
administrative proceeding that is inconsistent with such characterization. Notwithstanding the foregoing, nothing contained in this paragraph shall or shall be deemed to modify or impair in any manner whatsoever the obligations from time to time
owing by the Company and/or its Subsidiaries to Laurus or its assigns under the Purchase Agreement, the March 2006 Note and the other Related Agreements referred to in the Purchase Agreement. 
 2. Reaffirmation of Security Documents. To induce the Holders to agree to the amendments evidenced by in this Amendment, each of the Company,
Biovax, AutovaxID, Biolender, BiolenderII and Accentia hereby: 
 (a) represents and warrants to Laurus that it has reviewed
and approved the terms and provisions of each of this Amendment, this Amendment and the other documents, instruments and agreements entered into in connection therewith (if any) (collectively, the “New Laurus Agreements”);

 (b) acknowledges, ratifies and confirms that all indebtedness incurred by, and all other obligations and liabilities of,
each of the Company, AutovaxID, Biolender, BiolenderII and Accentia under each of the New Laurus Agreements are (i) “Obligations” under, and as defined in the Subsidiary Guaranty, (ii) “Obligations” under, and as
defined in, the Master Security Agreement, (iii) “Obligations” under, and as defined in, the Stock Pledge Agreement, (iv) “Obligations” under, and as defined in the Accentia Guaranty, and
(v) “Obligations” under, and as defined in, the Accentia Stock Pledge Agreement; 
 (c) acknowledges, ratifies
and confirms that each of the New Laurus Agreements are (i) “Documents” under, and as defined in, each of the Subsidiary Guaranty, the Master Security Agreement, the Stock Pledge Agreement and the Accentia Stock Pledge Agreement and
(ii) “Related Agreements” under, and as defined in, the Accentia Guaranty; 
 (d) acknowledges, ratifies and
confirms that all of the terms, conditions, representations and covenants contained in the Existing Security and Guaranty Agreements are in full force and effect and shall remain in full force and effect after giving effect to the execution and
effectiveness of each of the New Laurus Agreements; 
 (e) represents and warrants that no offsets, counterclaims or defenses
exist as of the date hereof with respect to any of the undersigned’s obligations under any Existing Security and Guaranty Agreement; and 
  

 3 

 (f) acknowledges, ratifies and confirms the grant by each of the Company, Biovax,
AutovaxID, Biolender, BiolenderII and Accentia to Laurus of a security interest in the assets of (including the equity interests owned by) each of the Company, Biovax, AutovaxID, Biolender, BiolenderII and Accentia, respectively, as more
specifically set forth in the Existing Security and Guaranty Agreements. 
 (g) releases, remises, acquits and forever
discharges each Holder and each Holder’s employees, agents, representatives, consultants, attorneys, fiduciaries, officers, directors, partners, predecessors, successors and assigns, subsidiary corporations, parent corporations, and related
corporate divisions (all of the foregoing hereinafter called the “Released Parties”), from any and all actions and causes of action, judgments, executions, suits, debts, claims, demands, liabilities, obligations, damages and
expenses of any and every character, known or unknown, direct and/or indirect, at law or in equity, of whatsoever kind or nature, for or because of any matter or things done, omitted or suffered to be done by any of the Released Parties prior to and
including the date of execution hereof, and in any way directly or indirectly arising out of or in any way connected to this Amendment, the Purchase Agreement, the Related Agreements referred to therein and any other document, instrument or
agreement made by any of the undersigned in favor of any Holder. 
 3. Conditions of Effectiveness. This Amendment shall become
effective as of April 1, 2007 upon satisfaction of the following conditions precedent: Laurus shall have received one copy of this Amendment duly executed by the Credit Parties. 
 4. Representations and Warranties. Each Credit Party hereby represents and warrants as follows: 
 (a) This Amendment and the Purchase Agreement and the Related Agreements referred to therein, as amended hereby, constitute legal, valid
and binding obligations of each Credit Party and are enforceable against each Credit Party in accordance with their respective terms. 
 (b) Upon the effectiveness of this Amendment, each Credit Party hereby reaffirms all covenants, representations and warranties made in the Purchase Agreement and the Related Agreements to the extent the same are not
amended hereby and agree that all such covenants, representations and warranties shall be deemed to have been remade as of the effective date of this Amendment. 
 (c) No Event of Default or Default has occurred and is continuing or would exist after giving effect to this Amendment. 
 (d) No Credit Party has any defense, counterclaim or offset with respect to the Purchase Agreement or any Related Agreement. 

5. Effect on the Loan Agreement. 
 (a) Upon the effectiveness of Sections 3 and 4 hereof, each reference in the Purchase Agreement and/or any Related Agreement to “this Agreement,” “hereunder,” “hereof,” “herein”
or words of like import shall mean and be a reference to the Purchase Agreement and/or such Related Agreement as amended hereby. 
  

 4 

 (b) Except as specifically amended herein, the Purchase Agreement, the Related Agreement,
and all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed. 
 (c) The execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of Laurus, nor
constitute a waiver of any provision of the Purchase Agreement or any Related Agreement, or any other documents, instruments or agreements executed and/or delivered under or in connection therewith. 
 6. Governing Law. This Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns
and shall be governed by and construed in accordance with the laws of the State of New York. 
 7. Headings. Section headings in this
Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose. 
 8. Counterparts; Facsimile. This Amendment may be executed by the parties hereto in one or more counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same agreement.
Any signature delivered by a party by facsimile transmission shall be deemed to be an original signature hereto. 
 * * * The remainder of
this page left intentionally blank – signature pages follow * * * 
  

 5 

 IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first written above. 
  

			
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ Steven Arikian,

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO
	
	BIOVAX, INC.
		
	By:	 	 /s/ Steven Arikian,

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO
	
	AUTOVAXID, INC.
		
	By:	 	 /s/ Steven Arikian,

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO
	
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	By:	 	 /s/ Francis E. O’Donnell, Jr.

	Name:	 	Francis E. O’Donnell, Jr., M.D.
	Title:	 	Chairman & CEO
	
	BIOLENDER, LLC
	By Biovest international, Inc., its managing member
		
	By:	 	 /s/ Steven Arikian,

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO
	
	BIOLENDERII, LLC
	By Biovest international, Inc., its managing member
		
	By:	 	 /s/ Steven Arikian,

	Name:	 	Steven Arikian, M.D.
	Title:	 	Chairman & CEO

  

 6 

			
	LAURUS MASTER FUND, LTD.
	By: Laurus Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan
	Title:	 	Senior Managing Director
	
	VALENS OFFSHORE SPV I, LTD.
	By: Valens Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan
	Title:	 	Authorized Signatory
	
	VALENS ONSHORE SPV I, LLC
	By: Valens Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Patrick Regan

	Name:	 	Patrick Regan
	Title:	 	Authorized Signatory

  

 7Amendment No. 1 to Overadvance Side Letter dated as of October 21, 2007

 Exhibit 10.1 
 AMENDMENT NO. 1 
 to OVERADVANCE SIDE-LETTER 
 This AMENDMENT NO. 1 to OVERADVANCE SIDE-LETTER (this “Amendment”), dated as of October 21, 2007, is entered into by and among
Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Parent”), Analytica International, Inc., a Florida corporation (“Analytica”), Teamm Pharmaceuticals, Inc., a Florida corporation
(“Teamm” and, together with the Parent and Analytica, the “Companies” and, each a “Company”) and Laurus Master Fund, Ltd., a Cayman Islands company (the “Purchaser”), for the
purpose of amending the terms of the Overadvance Side Letter dated as of August 29, 2007 by and among the Companies and Laurus (as amended, modified or supplemented from time to time, the “Overadvance Side-Letter”) issued in
connection with the Amended and Restated Security Agreement, dated as of April 29, 2005, and amended and restated as of February 13, 2006 by and among the Companies and Laurus (as amended and restated, further amended, modified or
supplemented from time to time, the “Security Agreement” and, together with Overadvance Side-Letter and the other Ancillary Agreements referred to in the Security Agreement, the “Loan Documents”). Capitalized
terms used herein without definition shall have the meanings ascribed to such terms in the Security Agreement. 
 WHEREAS, the Companies have
requested that the maturity and termination date of the Overadvances set forth in the Overadvance Side Letter be extended and Laurus has agreed to extend the Period (as defined in the Overadvance Side Letter), on the terms and conditions set forth
herein, such. 
 NOW, THEREFORE, in consideration of the above, and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereto agree as follows: 
 1. The first sentence in the fourth paragraph of the Overadvance Side
Letter is hereby amended by deleting the date “October 21, 2007” appearing therein and inserting the date “March 31, 2008” in lieu thereof. 
 2. Each Company and Laurus hereby acknowledges that certain payments to be made to Laurus by AMERICAN STOCK TRANSFER & TRUST COMPANY, a financial institution chartered under the laws of the State of New York
(“AST”), in connection with the requirements of the Escrow Agreement, dated as of September 29, 2006 by and between the Parent and AST may exceed the amount required to pay principal and accrued interest as required under the Loan
Documents, other than with respect to payments of principal on the Revolving Note (as defined in the Security Agreement) and the Overadvance (as defined in the Overadvance Side-Letter) (such amounts in excess of the required amortization payments
are hereinafter referred to as the “Excess Payment”). Each Company hereby acknowledges and affirms that the “Maximum Third Overadvance Limit” under and as defined in the Overadvance Side Letter shall be permanently reduced on a
dollar for dollar basis for that Excess Payment portion of each payment received from AST, in connection with the requirements of the Escrow Agreement, as amended, modified or supplemented from time to time. 
  

 3. Each Company hereby acknowledges and affirms that the amount of the Overadvance outstanding as of the
date hereof is $4,400,000. 
 4. (a) The Parent hereby agrees to issue a warrant no later than October 21, 2007, in form and substance
satisfactory to Laurus (the “Third Overadvance Warrant”) as attached as Exhibit A, to purchase up to 4,024,398 shares of Common Stock of the Parent, each with a par value of $0.001 (the “Third Overadvance Warrant
Shares”). The defined term “Warrants” in the Security Agreement shall be deemed to include the Common Stock Purchase Warrant issued on the Closing Date and the Third Overadvance Warrant and the defined term “Warrant
Shares” in the Security Agreement shall be deemed to include the Third Overadvance Warrant Shares. 
 (b) The Parent further agrees that
if at any time after the date hereof there is not an effective Registration Statement covering all of the Third Overadvance Warrant Shares issued hereunder and the Parent shall determine to prepare and file with the Securities and Exchange
Commission a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or
their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with stock option or other employee benefit plans, then the Parent
shall send to Laurus written notice of such determination and, if within fifteen (15) days after receipt of such notice, Laurus shall so request in writing, the Parent shall include in such registration statement all or any part of such Third
Overadvance Warrant Shares Laurus requests to be registered, to the extent the Company may do so without violating registration rights of others which exist as of the Amendment Effective Date (as defined below), subject to customary underwriter
cutbacks applicable to all holders of registration rights and subject to obtaining any required consent of any selling stockholder(s) to such inclusion under such registration statement. 
 (c) The parties hereto agree that the fair market value of the Third Overadvance Warrant (as reasonably determined by the parties) received in
consideration of the amendments to the Overadvance Side-Letter made by Laurus hereunder is hereby designated as additional interest. The parties further agree to file all applicable tax returns in accordance with such characterization and
shall not take a position on any tax return or in any judicial or administrative proceeding that is inconsistent with such characterization. Notwithstanding the foregoing, nothing contained in this paragraph shall or shall be deemed to modify or
impair in any manner whatsoever the Companies’ obligations from time to time owing to Laurus under the Loan Documents. 
 5. The amendment set forth above shall be effective as of the date first above written (the “Amendment Effective Date”) on the date when (i) each of the Companies and Laurus shall have executed and each of the
Companies shall have delivered to Laurus its respective counterpart to this Amendment and (ii) the Parent shall have duly executed (with witness) and delivered to Laurus the Third Overadvance Warrant. 
 6. Except as specifically set forth in this Amendment, there are no other amendments, modifications or waivers to the Loan Documents, and all of the
other forms, terms and provisions of the Loan Documents remain in full force and effect. 
  

					
		  	2	  	

 7. Except as set forth in Schedule I hereto, each Company hereby represents and warrants to Laurus that
(i) no Event of Default exists on the date hereof, after giving effect to this Amendment, (ii) on the date hereof, all representations, warranties and covenants made by each Company in connection with the Loan Documents are true, correct
and complete and (iii) on the date hereof, all of the Company’s and its Subsidiaries’ covenant requirements have been met. 
 8. From and after the Amendment Effective Date, all references in the Loan Documents and in the other Ancillary Agreements to the Overadvance Side Letter shall be deemed to be references to the Overadvance Side Letter, as the case may be,
as modified hereby. 
 9. The Parent understands that the Parent has an affirmative obligation to make prompt public disclosure of material
agreements and material amendments to such agreements. It is the Parent’s determination that neither this Amendment nor the terms and provisions of this Amendment, (collectively, the “Information”) are material. The Company has had an
opportunity to consult with counsel concerning this determination. The Company hereby agrees that Laurus shall not be in violation of any duty to the Company or its shareholders, nor shall Laurus be deemed to be misappropriating any information of
the Company, if Laurus sells shares of common stock of the Company, or otherwise engages in transactions with respect to securities of the Company, while in possession of the Information. 
 10. This Amendment shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the benefit of and
be enforceable by each of the parties hereto and their respective successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may be
executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. 
 [The
remainder of this page is intentionally left blank] 
  

					
		  	3	  	

 IN WITNESS WHEREOF, each of the Company and Laurus has caused this Amendment to the Overadvance
Side Letter to be signed in its name effective as of this 21st day of October 2007. 
  

					
	ACCENTIA BIOPHARMACEUTICALS, INC.
			
	By:	 	  /s/ Alan Pearce
	 	10/31/07
	Name:	 	Alan M. Pearce	 	
	Title:	 	CFO	 	
	
	ANALYTICA INTERNATIONAL, INC.
			
	By:	 	 /s/ James A. McNulty	 	10/31/07
	Name:	 	James A. McNulty, CPA
	Title:	 	Secretary/Treasurer
	
	TEAMM PHARMACEUTICALS, INC.
			
	By:	 	 /s/ James A. McNulty	 	10/31/07
	Name:	 	James A. McNulty, CPA
	Title:	 	Secretary/Treasurer
	
	LAURUS MASTER FUND, LTD.
	By:	 	Laurus Capital Management, LLC, its investment manager
			
	By:	 	/s/ Patrick Regan	 	 
	Name:	 	Patrick Regan
	Title:	 	Senior Managing Director

 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT AS TO THIS WARRANT UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ACCENTIA BIOPHARMACEUTICALS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
 Right to Purchase up to 4,024,398 of Common Stock of Accentia Biopharmaceuticals, Inc. 
 (subject to adjustment as provided herein) 
 COMMON STOCK PURCHASE WARRANT

  

			
	No. 1537	  	Issue Date: October 31, 2007

 ACCENTIA BIOPHARMACEUTICALS, INC., a corporation organized under the laws of the State of Florida
(the “Company”), hereby certifies that, for value received, LAURUS MASTER FUND, LTD., or assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company (as defined herein) from and after
the Warrant Repurchase date as provided in Paragraph 1.5 of this Warrant and at any time or from time to time before 5:00 p.m., New York time, through the close of business October 31, 2014 (the “Expiration Date”), up to 4,024,398
fully paid and nonassessable shares of Common Stock (as hereinafter defined), $0.001 par value per share at the applicable Exercise Price per share (as defined below). The number and character of such shares of Common Stock and the applicable
Exercise Price per share are subject to adjustment as provided herein. 
 As used herein the following terms, unless the context otherwise
requires, have the following respective meanings: 
 (a) The term “Company” shall include Accentia
Biopharmaceuticals, Inc. and any person or entity that shall succeed, or assume the obligations of, Accentia Biopharmaceuticals, Inc. hereunder. 
 (b) The term “Common Stock” includes (i) the Company’s Common Stock, par value $0.001 per share; and (ii) any other securities into which or for which any of the securities described in the
preceding clause (i) may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of assets or otherwise. 
 (c) The term “Other Securities” refers to any stock (other than Common Stock) and other securities of the Company or any other person (corporate or otherwise) which the holder of the Warrant at any time
shall be entitled to receive, or shall have 

  

 5 

 
received, on the exercise of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have been issued in
exchange for or in replacement of Common Stock or Other Securities pursuant to Section 4 or otherwise. 
 (d) The
“Exercise Price” applicable under this Warrant shall be equal to $2.67. 
 Exercise of Warrant. 
 Number of Shares Issuable upon Exercise. From and after the date hereof through and including the Expiration Date, the Holder shall be entitled to
receive, upon exercise of this Warrant in whole or in part, by delivery of an original or fax copy of an exercise notice in the form attached hereto as Exhibit A (the “Exercise Notice”), shares of Common Stock of the Company, subject to
adjustment pursuant to Section 4. 
 Fair Market Value. For purposes hereof, the “Fair Market Value” of a share of
Common Stock as of a particular date (the “Determination Date”) shall mean: 
 If the Company’s Common Stock is
traded on the American Stock Exchange or another national exchange or is quoted on the National or SmallCap Market of The Nasdaq Stock Market, Inc. (“Nasdaq”), then the closing or last sale price, respectively, reported for the last
business day immediately preceding the Determination Date. 
 If the Company’s Common Stock is not traded on the American
Stock Exchange or another national exchange or on the Nasdaq but is traded on the NASD Over The Counter Bulletin Board, then the mean of the average of the closing bid and asked prices reported for the last business day immediately preceding the
Determination Date. 
 Except as provided in clause (d) below, if the Company’s Common Stock is not publicly traded,
then as the Holder and the Company agree or in the absence of agreement by arbitration in accordance with the rules then in effect of the American Arbitration Association, before a single arbitrator to be chosen from a panel of persons qualified by
education and training to pass on the matter to be decided. 
 If the Determination Date is the date of a liquidation,
dissolution or winding up, or any event deemed to be a liquidation, dissolution or winding up pursuant to the Company’s charter, then all amounts to be payable per share to holders of the Common Stock pursuant to the charter in the event of
such liquidation, dissolution or winding up, plus all other amounts to be payable per share in respect of the Common Stock in liquidation under the charter, assuming for the purposes of this clause (d) that all of the shares of Common Stock
then issuable upon exercise of the Warrant are outstanding at the Determination Date. 
  

 6 

 Company Acknowledgment. The Company will, at the time of the exercise of this Warrant, upon the
request of the holder hereof acknowledge in writing its continuing obligation to afford to such holder any rights to which such holder shall continue to be entitled after such exercise in accordance with the provisions of this Warrant. If the holder
shall fail to make any such request, such failure shall not affect the continuing obligation of the Company to afford to such holder any such rights. 
 Trustee for Warrant Holders. In the event that a bank or trust company shall have been appointed as trustee for the holders of this Warrant pursuant to Subsection 3.2, such bank or trust company shall have all
the powers and duties of a warrant agent (as hereinafter described) and shall accept, in its own name for the account of the Company or such successor person as may be entitled thereto, all amounts otherwise payable to the Company or such successor,
as the case may be, on exercise of this Warrant pursuant to this Section 1. 
 Right to Repurchase. Notwithstanding anything
contained herein to the contrary, at any time prior to the first to occur of March 31, 2008 or the public announcement of unblinded top line results of the first SinuNaseTM clinical trial (the “Warrant Repurchase Date”), the
Company may, at its sole discretion, provide Holder with written notice (the “Notice of Repurchase”) of its intent to repurchase the Warrant for an aggregate purchase price of Four Million Dollars ($4,000,000) (the “Warrant Repurchase
Price”). The Warrant Repurchase Price shall be paid in full in cash within twenty calendar days following the Notice of Repurchase. Upon Notice of Repurchase and payment of the Warrant Repurchase Price, this Warrant shall be cancelled and
Holder shall have no further rights hereunder. 
 Procedure for Exercise. 
 Delivery of Stock Certificates, Etc., on Exercise. The Company agrees that the shares of Common Stock purchased upon exercise of this Warrant shall
be deemed to be issued to the Holder as the record owner of such shares as of the close of business on the date on which this Warrant shall have been surrendered and payment made for such shares in accordance herewith. As soon as practicable after
the exercise of this Warrant in full or in part, and in any event within three (3) business days thereafter, the Company at its expense (including the payment by it of any applicable issue taxes) will cause to be issued in the name of and
delivered to the Holder, or as such Holder (upon payment by such Holder of any applicable transfer taxes) may direct in compliance with applicable securities laws, a certificate or certificates for the number of duly and validly issued, fully paid
and nonassessable shares of Common Stock (or Other Securities) to which such Holder shall be entitled on such exercise, plus, in lieu of any fractional share to which such holder would otherwise be entitled, cash equal to such fraction multiplied by
the then Fair Market Value of one full share, together with any other stock or other securities and property (including cash, where applicable) to which such Holder is entitled upon such exercise pursuant to Section 1 or otherwise. 

Exercise. 
 Payment
may be made either (i) in cash or by certified or official bank check payable to the order of the Company equal to the applicable aggregate Exercise Price, (ii)

  

 7 

 
by delivery of this Warrant, or shares of Common Stock and/or Common Stock receivable upon exercise of this Warrant in accordance with the formula set forth
in subsection (b) below, or (iii) by a combination of any of the foregoing methods, for the number of Common Shares specified in such Exercise Notice (as such exercise number shall be adjusted to reflect any adjustment in the total number
of shares of Common Stock issuable to the Holder per the terms of this Warrant) and the Holder shall thereupon be entitled to receive the number of duly authorized, validly issued, fully-paid and non-assessable shares of Common Stock (or Other
Securities) determined as provided herein. 
 Notwithstanding any provisions herein to the contrary, if the Fair Market Value
of one share of Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant for cash, the Holder may elect to receive shares equal to the value (as determined below) of this
Warrant (or the portion thereof being exercised) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Exercise Notice in which event the Company shall issue to the Holder a number of shares of
Common Stock computed using the following formula: 
  

					
	X =	 	    Y(A-B)    	  	
		 	A	  	
		
	Where X =	 	the number of shares of Common Stock to be issued to the Holder
		
	Y =	 	the number of shares of Common Stock purchasable under this Warrant or, if only a portion of this Warrant is being exercised, the portion of this Warrant being exercised (at the date
of such calculation)
		
	A =	 	the Fair Market Value of one share of the Company’s Common Stock (at the date of such calculation)
		
	B =	 	the Exercise Price per share (as adjusted to the date of such calculation)

 Effect of Reorganization, Etc.; Adjustment of Exercise Price. 
 Reorganization, Consolidation, Merger, Etc. In case at any time or from time to time, the Company shall (a) effect a reorganization,
(b) consolidate with or merge into any other person, or (c) transfer all or substantially all of its properties or assets to any other person under any plan or arrangement contemplating the dissolution of the Company, then, in each such
case, as a condition to the consummation of such a transaction, proper and adequate provision shall be made by the Company whereby the Holder, on the exercise hereof as provided in Section 1 at any time after the consummation of such
reorganization, consolidation or merger or the effective date of such dissolution, as the case may be, shall receive, in lieu of the Common Stock (or Other Securities) issuable on such exercise prior to such consummation or such effective date, the
stock and other securities and property (including cash) to which such Holder would have been entitled upon such consummation or in connection with such dissolution, as the case may be, if such Holder had so exercised this Warrant, immediately prior
thereto, all subject to further adjustment thereafter as provided in Section 4. 
  

 8 

 Dissolution. In the event of any dissolution of the Company following the transfer of all or
substantially all of its properties or assets, the Company, concurrently with any distributions made to holders of its Common Stock, shall at its expense deliver or cause to be delivered to the Holder the stock and other securities and property
(including cash, where applicable) receivable by the Holder pursuant to Section 3.1, or, if the Holder shall so instruct the Company, to a bank or trust company specified by the Holder and having its principal office in New York, NY as trustee
for the Holder. 
 Continuation of Terms. Upon any reorganization, consolidation, merger or transfer (and any dissolution following
any transfer) referred to in this Section 3, this Warrant shall continue in full force and effect and the terms hereof shall be applicable to the shares of stock and other securities and property receivable on the exercise of this Warrant after
the consummation of such reorganization, consolidation or merger or the effective date of dissolution following any such transfer, as the case may be, and shall be binding upon the issuer of any such stock or other securities, including, in the case
of any such transfer, the person acquiring all or substantially all of the properties or assets of the Company, whether or not such person shall have expressly assumed the terms of this Warrant as provided in Section 4. In the event this
Warrant does not continue in full force and effect after the consummation of the transactions described in this Section 3, then the Company’s securities and property (including cash, where applicable) receivable by the Holder will be
delivered to the Holder or the Trustee as contemplated by Section 3.2. 
 Extraordinary Events Regarding Common Stock. In the
event that the Company shall (a) issue additional shares of the Common Stock as a dividend or other distribution on outstanding Common Stock or any preferred stock issued by the Company, (b) subdivide its outstanding shares of Common
Stock, (c) combine its outstanding shares of the Common Stock into a smaller number of shares of the Common Stock, then, in each such event, the Exercise Price shall, simultaneously with the happening of such event, be adjusted by multiplying
the then Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event, and the product so obtained shall thereafter be the Exercise Price then in effect. The Exercise Price, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events
described herein in this Section 4. The number of shares of Common Stock that the holder shall thereafter, on the exercise hereof as provided in Section 1, be entitled to receive shall be adjusted to a number determined by multiplying the
number of shares of Common Stock that would otherwise (but for the provisions of this Section 4) be issuable on such exercise by a fraction of which (a) the numerator is the Exercise Price that would otherwise (but for the provisions of
this Section 4) be in effect, and (b) the denominator is the Exercise Price in effect on the date of such exercise (taking into account the provisions of this Section 4). 
 Certificate as to Adjustments. In each case of any adjustment or readjustment in the shares of Common Stock (or Other Securities) issuable on the
exercise of this Warrant, the Company at its expense will upon the Holder’s request promptly cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment or 

  

 9 

 
readjustment and showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (a) the consideration
received or receivable by the Company for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or sold, (b) the number of shares of Common Stock (or Other Securities) outstanding or deemed to
be outstanding, and (c) the Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior to such adjustment or readjustment and as adjusted or readjusted as provided in this
Warrant. The Company will forthwith mail a copy of each such certificate to the holder and any Warrant agent of the Company (appointed pursuant to Section 11 hereof). 
 Reservation of Stock, Etc., Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely for issuance and
delivery on the exercise of this Warrant, shares of Common Stock (or Other Securities) from time to time issuable on the exercise of this Warrant. 
 Assignment; Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced hereby, may be transferred by any registered holder hereof (a “Transferor”) in whole or in part.
On the surrender for exchange of this Warrant, with the Transferor’s endorsement in the form of Exhibit B attached hereto (the “Transferor Endorsement Form”) and together with evidence reasonably satisfactory to the Company
demonstrating compliance with applicable securities laws, which shall include, without limitation, a legal opinion from the Transferor’s counsel (at the Company’s expense) that such transfer is exempt from the registration requirements of
applicable securities laws, the Company at its expense (but with payment by the Transferor of any applicable transfer taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor, in the name of the
Transferor and/or the transferee(s) specified in such Transferor Endorsement Form (each a “Transferee”), calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face or faces of the
Warrant so surrendered by the Transferor. 
 Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of
the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement or security reasonably satisfactory in form and amount to the Company or, in
the case of any such mutilation, on surrender and cancellation of this Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor. 
 Registration Rights. The Holder has been granted certain piggyback registration rights by the Company. These registration rights are set forth in
Amendment No. 1 to Overadvance Side Letter entered into by the Company and Holder dated as of the date hereof, as the same may be amended, modified and/or supplemented from time to time. 
 Maximum Exercise. Notwithstanding anything contained herein to the contrary, the Holder shall not be entitled to exercise this Warrant in
connection with that number of shares of Common Stock which would exceed the difference between (i) 9.99% of the issued and outstanding shares of Common Stock and (ii) the number of shares of Common Stock beneficially owned by the Holder.
For purposes of the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities 

  

 10 

 
Exchange Act of 1934, as amended, and Regulation 13d-3 thereunder. The limitation described in the first sentence of this Section 10 shall automatically
become null and void without any notice to the Company upon the occurrence and during the continuance of an Event of Default (as defined in the Security Agreement dated as of the date hereof among the Holder, the Company and various subsidiaries of
the Company, as amended, modified, restated and/or supplemented from time to time), or upon 75 days prior notice to the Company. 
 Warrant Agent. The Company may, by written notice to the each Holder of the Warrant, appoint an agent for the purpose of issuing Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 1,
exchanging this Warrant pursuant to Section 7, and replacing this Warrant pursuant to Section 8, or any of the foregoing, and thereafter any such issuance, exchange or replacement, as the case may be, shall be made at such office by such
agent. 
 Transfer on the Company’s Books. Until this Warrant is transferred on the books of the Company, the Company may treat
the registered holder hereof as the absolute owner hereof for all purposes, notwithstanding any notice to the contrary. 
 Notices,
Etc. All notices and other communications from the Company to the Holder shall be mailed by first class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company in writing by such Holder or, until
any such Holder furnishes to the Company an address, then to, and at the address of, the last Holder who has so furnished an address to the Company. 
 Miscellaneous. This Warrant and any term hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge
or termination is sought. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. ANY ACTION BROUGHT CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS
WARRANT SHALL BE BROUGHT ONLY IN STATE COURTS OF NEW YORK OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK; PROVIDED, HOWEVER, THAT THE HOLDER MAY CHOOSE TO WAIVE THIS PROVISION AND BRING AN ACTION OUTSIDE THE STATE OF NEW YORK. The
individuals executing this Warrant on behalf of the Company agree to submit to the jurisdiction of such courts and waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorneys’ fees and
costs. In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified
to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Warrant. The headings in this Warrant are for
purposes of reference only, and shall not limit or otherwise affect any of the terms hereof. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision hereof. The Company
acknowledges that legal counsel participated in the preparation of this Warrant and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of
this Warrant to favor any party against the other party. 
  

 11 

 [BALANCE OF PAGE INTENTIONALLY LEFT BLANK; 
 SIGNATURE PAGE FOLLOWS] 
  

 12 

 IN WITNESS WHEREOF, the Company has executed this Warrant as of the date first written above. 

 

							
	 	 	 	 	ACCENTIA BIOPHARMACEUTICALS, INC.
				
	WITNESS:	 		 		 	
		 		 	By:	 	  

		 		 	Name:	 	
	  
	 		 	Title:	 	

  

 13 

 EXHIBIT A 
 FORM OF SUBSCRIPTION 
 (To Be Signed Only On Exercise Of Warrant) 
  

	TO:	Accentia Biopharmaceuticals, Inc. 

							
	  
	  		  		  	
	  
	  		  		  	

 Attention: Chief Financial Officer 
 The undersigned, pursuant to the provisions set forth in the attached Warrant (No.     ), hereby irrevocably elects to
purchase (check applicable box): 
  

			
	                          
	  	             shares of the common stock covered by such warrant; or
		
	  
	  	the maximum number of shares of common stock covered by such warrant pursuant to the cashless exercise procedure set forth in Section 2.
	
	 The undersigned herewith makes payment of the full Exercise Price for such shares at the price per share provided for in such Warrant, which is
$                    . Such payment takes the form of (check applicable box or boxes):

		
	                          
	  	$                     in lawful money of the United States; and/or
		
	                          
	  	the cancellation of such portion of the attached Warrant as is exercisable for a total of              shares of Common Stock
(using a Fair Market Value of $             per share for purposes of this calculation); and/or
		
	                          
	  	the cancellation of such number of shares of Common Stock as is necessary, in accordance with the formula set forth in Section 2.2, to exercise this Warrant with respect to the maximum number of
shares of Common Stock purchasable pursuant to the cashless exercise procedure set forth in Section 2.
	
	 The undersigned requests that the certificates for such shares be issued in the name of, and delivered to
                                        
                     whose address is
                                        
                                       
 .

 The undersigned represents and warrants that all offers and sales by the undersigned of the
securities issuable upon exercise of the within Warrant shall be made pursuant to registration of the Common Stock under the Securities Act of 1933, as amended (the “Securities Act”) or pursuant to an exemption from registration under the
Securities Act. 
  

									
	 Dated:
	 	  
	 		  	  

		 		 		  	(Signature must conform to name of holder as specified on the face of the Warrant)
		 		 		  	Address:	  	  

		 		 		  		  	  

  

 14 

 EXHIBIT B 
 FORM OF TRANSFEROR ENDORSEMENT 
 (To Be Signed Only On Transfer Of Warrant) 
 For value received, the undersigned hereby sells, assigns, and transfers unto the person(s) named below under the heading “Transferees” the
right represented by the within Warrant to purchase the percentage and number of shares of Common Stock of Accentia Biopharmaceuticals, Inc. into which the within Warrant relates specified under the headings “Percentage Transferred” and
“Number Transferred,” respectively, opposite the name(s) of such person(s) and appoints each such person Attorney to transfer its respective right on the books of Accentia Biopharmaceuticals, Inc. with full power of substitution in the
premises. 
  

							
	 Transferees
	  	 Address
	  	 Percentage
 Transferred
	  	 Number
 Transferred

		  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

  

									
	 Dated:
	  	  
	 		 	  

		  		 		 	(Signature must conform to name of holder as specified on the face of the Warrant)
		  		 		 	Address:	 	  

		  		 		 		 	  

				
		  		 		 	SIGNED IN THE PRESENCE OF:
				
		  		 		 	  

		  		 		 	(Name)
			
	 ACCEPTED AND AGREED:
	 		 	
	 [TRANSFEREE]
	 		 	
			
	  
	 		 	
	 (Name)
	 		 	

  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]